243 related articles for article (PubMed ID: 21239502)
1. Resveratrol-mediated SIRT-1 interactions with p300 modulate receptor activator of NF-kappaB ligand (RANKL) activation of NF-kappaB signaling and inhibit osteoclastogenesis in bone-derived cells.
Shakibaei M; Buhrmann C; Mobasheri A
J Biol Chem; 2011 Apr; 286(13):11492-505. PubMed ID: 21239502
[TBL] [Abstract][Full Text] [Related]
2. Specnuezhenide suppresses diabetes-induced bone loss by inhibiting RANKL-induced osteoclastogenesis.
Ye X; Jiang J; Yang J; Yan W; Jiang L; Chen Y
Acta Biochim Biophys Sin (Shanghai); 2022 Aug; 54(8):1080-1089. PubMed ID: 35929595
[TBL] [Abstract][Full Text] [Related]
3. The key royal jelly component 10-hydroxy-2-decenoic acid protects against bone loss by inhibiting NF-κB signaling downstream of FFAR4.
Tsuchiya Y; Hayashi M; Nagamatsu K; Ono T; Kamakura M; Iwata T; Nakashima T
J Biol Chem; 2020 Aug; 295(34):12224-12232. PubMed ID: 32647011
[TBL] [Abstract][Full Text] [Related]
4. Cucumber seed polypeptides regulate RANKL-induced osteoclastogenesis through OPG/RANKL/RANK and NF-κB.
Yu T; Liu X; Jiang M; Li Y; Su H; Niu B
In Vitro Cell Dev Biol Anim; 2024 Jan; 60(1):54-66. PubMed ID: 38123756
[TBL] [Abstract][Full Text] [Related]
5. Nuclear Factor-Kappa B Regulation of Osteoclastogenesis and Osteoblastogenesis.
Boyce BF; Li J; Yao Z; Xing L
Endocrinol Metab (Seoul); 2023 Oct; 38(5):504-521. PubMed ID: 37749800
[TBL] [Abstract][Full Text] [Related]
6. Iguratimod suppresses sclerostin and receptor activator of NF-κB ligand production via the extracellular signal-regulated kinase/early growth response protein 1/tumor necrosis factor alpha pathway in osteocytes and ameliorates disuse osteoporosis in mice.
Miura T; Etani Y; Noguchi T; Hirao M; Takami K; Goshima A; Kurihara T; Fukuda Y; Ochiai N; Kanamoto T; Nakata K; Okada S; Ebina K
Bone; 2024 Apr; 181():117026. PubMed ID: 38325651
[TBL] [Abstract][Full Text] [Related]
7. Koumine inhibits RANKL-induced ubiquitination and NF-κB activation to prevent ovariectomy and aging-induced bone loss.
You J; Xu D; Zhang C; Chen Y; Huang S; Bian H; Lv J; Chen D; Su L; Yin H; Li Y; Wang Y
J Cell Biochem; 2024 Jan; 125(1):100-114. PubMed ID: 38031891
[TBL] [Abstract][Full Text] [Related]
8. Isoquercitrin attenuates the osteoclast-mediated bone loss in rheumatoid arthritis via the Nrf2/ROS/NF-κB pathway.
Liu Y; Li TQ; Bai J; Liu WL; Wang ZR; Feng C; Pu LL; Wang XX; Liu H
Biochim Biophys Acta Mol Basis Dis; 2024 Feb; 1870(2):166977. PubMed ID: 38065271
[TBL] [Abstract][Full Text] [Related]
9. Hyaluronan-mediated CD44 interaction with p300 and SIRT1 regulates beta-catenin signaling and NFkappaB-specific transcription activity leading to MDR1 and Bcl-xL gene expression and chemoresistance in breast tumor cells.
Bourguignon LYW; Xia W; Wong G
J Biol Chem; 2009 Jan; 284(5):2657-2671. PubMed ID: 19047049
[TBL] [Abstract][Full Text] [Related]
10. Mitigation of inflammatory bowel disease-related osteoporosis by oxyberberine: Insights into the RANKL/NF-κB signaling pathway.
Chen T; Ai G; Liang G; Zeng L; Zhao D; Liu J; Dou Y
Biomed Pharmacother; 2024 May; 174():116523. PubMed ID: 38574627
[TBL] [Abstract][Full Text] [Related]
11. Protective effects of piperlongumine against adjuvant-induced arthritis in rats through modulating OPG/RANKL/NF-κB signaling pathway.
Wu SD; Wu XJ; Wang TT; Jiang F; Hu MW; Li R; Liu J; Cai L
J Pharm Pharmacol; 2024 Jun; 76(6):646-655. PubMed ID: 38334976
[TBL] [Abstract][Full Text] [Related]
12. Pan-histone deacetylase inhibitor vorinostat suppresses osteoclastic bone resorption through modulation of RANKL-evoked signaling and ameliorates ovariectomy-induced bone loss.
Peng X; Wang T; Wang Q; Zhao Y; Xu H; Yang H; Gu Y; Tao Y; Yan B; Xu Y; Geng D
Cell Commun Signal; 2024 Mar; 22(1):160. PubMed ID: 38439009
[TBL] [Abstract][Full Text] [Related]
13. A Bone Anabolic Effect of RANKL in a Murine Model of Osteoporosis Mediated Through FoxP3+ CD8 T Cells.
Buchwald ZS; Yang C; Nellore S; Shashkova EV; Davis JL; Cline A; Ko J; Novack DV; DiPaolo R; Aurora R
J Bone Miner Res; 2015 Aug; 30(8):1508-22. PubMed ID: 25656537
[TBL] [Abstract][Full Text] [Related]
14. DNA damage drives accelerated bone aging via an NF-κB-dependent mechanism.
Chen Q; Liu K; Robinson AR; Clauson CL; Blair HC; Robbins PD; Niedernhofer LJ; Ouyang H
J Bone Miner Res; 2013 May; 28(5):1214-28. PubMed ID: 23281008
[TBL] [Abstract][Full Text] [Related]
15. A steroid like phytochemical Antcin M is an anti-aging reagent that eliminates hyperglycemia-accelerated premature senescence in dermal fibroblasts by direct activation of Nrf2 and SIRT-1.
Senthil KK; Gokila VM; Mau JL; Lin CC; Chu FH; Wei CC; Liao VH; Wang SY
Oncotarget; 2016 Sep; 7(39):62836-62861. PubMed ID: 27542238
[TBL] [Abstract][Full Text] [Related]
16. Binding-induced fibrillogenesis peptide inhibits RANKL-mediated osteoclast activation against osteoporosis.
Liang QL; Xu HG; Yu L; Ding MR; Li YT; Qi GF; Zhang K; Wang L; Wang H; Cui X
Biomaterials; 2023 Nov; 302():122331. PubMed ID: 37741149
[TBL] [Abstract][Full Text] [Related]
17. New Generation of Meso and Antiprogestins (SPRMs) into the Osteoporosis Approach.
Woźniczka M; Błaszczak-Świątkiewicz K
Molecules; 2021 Oct; 26(21):. PubMed ID: 34770897
[TBL] [Abstract][Full Text] [Related]
18. Discovery of a novel homoisoflavonoid derivative 5g for anti-osteoclastic bone loss via targeting FGFR1.
Chen Z; Encarnacion AM; Rajan RPS; Yao H; Lee S; Kim E; Lee TH
Eur J Med Chem; 2024 Apr; 270():116335. PubMed ID: 38555854
[TBL] [Abstract][Full Text] [Related]
19. AMPK negatively regulates RANKL-induced osteoclast differentiation by controlling oxidative stress.
Tanaka M; Inoue H; Takahashi N; Uehara M
Free Radic Biol Med; 2023 Aug; 205():107-115. PubMed ID: 37270032
[TBL] [Abstract][Full Text] [Related]
20. Expression and functional characterization of bovine receptor activator of NF-κB ligand (RANKL).
Chapuis AF; Alfituri OA; Hope JC; Stevens J; Moore J; Mclean K; Androscuk D; Dry I
Vet Immunol Immunopathol; 2024 Feb; 268():110705. PubMed ID: 38157760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
